Female doctor advising patient in hospital office during regular medical exam, healthcare and prevention concept.

MeTree

MANAGEMENT: Lori Orlando
DUKE INVENTOR: Geoff Ginsburg

MeTree is a family health history tool. Prior to an appointment, the doctor’s office will send an app-based survey for your/your family health history. Based on this data, the product will run algorithms, generate a report, and provide recommendations on lifestyle interventions with an overall goal of building a database of health, diseases, and outcomes.

metree logo

Family history in primary care

The systematic collection of family health history (FHH) can identify individuals at increased risk for common diseases including cardiovascular disease, diabetes, and cancer; many evidence-based guidelines rely upon risk stratification using FHH to guide the appropriate use of alternative (non-routine) screening procedures (such as breast MRI), diagnostic tests, and/or genetic counseling.

Unfortunately there are several barriers to the adequate collection of FHH within routine primary care: lack of patient preparation to provide FHH, the amount of time needed to collect FHH, lack of standardization, and limited training in synthesizing FHH data into a clinically actionable care plan.

MeTree

To address these issues, we have created a web-based patient-entered risk stratification and clinical decision support tool, MeTree, with the following design goals:

  • Develop a collection interface that is easy for patients to use and facilitates collection of all the necessary FHH and personal history components to perform risk stratification (full 3-generation pedigree with age of disease onset, current age or age of death, and cause of death for each relative)
  • Provide lay level and technical decision support that is clinically actionable for providers, activating for patients, and easy for patients and providers to understand • Base decision support upon guidelines widely accepted by PCPs and provide just-in-time education within the reports about what criteria triggered the recommendation, points to consider about the recommendation, data such as NNT, references to the guidelines, and links to additional resources
  • Capitalize on the patient-provider encounter to encourage discussions of preventive health and disease risk management.

MeTree will be available as an independent web-service that provides risk stratification and clinical decision support for the following conditions: breast cancer, ovarian cancer, colon cancer, hereditary cancer syndromes, coronary artery disease, hereditary cardiovascular conditions, stroke, aortic aneurysm, diabetes, and hereditary liver diseases (such as hemochromatosis).

security camera

Airgus

MANAGEMENT: Daniel Reichman
DUKE INVENTOR: Jordan Malof, Leslie Collins
ai-rgus.com

AᴉRGUS is an AI-based, low-cost, easy to use, and highly accurate solution. AᴉRGUS automatically inspects each camera and alerts you when the view is compromised by:

▪ Blur ▪ Tilt ▪ Tamper ▪ Obstruction ▪ Glare ▪ Black/blank screen ▪ More on request

ai-rgus logo

AᴉRGUS Dashboard

AᴉRGUS’s simple user interface saves operators’ time by streamlining the camera inspection process. You will also get reports, alerts, statistics and even work orders to make correcting your cameras’ wellness easy.

airgus dashboard
doctor holding clipboard with 3d heart overlay

Heart View Medical APS

MANAGEMENT:
DUKE INVENTOR: Olaf von Ramm
heartviewmedical.com

Our vision is to redefine the cardiology community’s understanding of the human heartbeat. HeartView Medical is developing the next generation high speed ultrasound system with extensive algorithms that enable automated quantitative measurements of the heart in a 3D view within one heart beat compared to current technology.

Heart View Medical Logo

ABOUT

 
Current state of the art: While imaging techniques are central to these advances, limitations exist in current imaging methods in their ability to rapidly record cardiac events (at physiologic speeds). At present, recording speeds are insufficient to properly link electrical activation to mechanical events and flow. ECG record activity in the 1-2 millisecond, i.e. 500-1000 events per second range while imaging methods (angiography, computed tomography-CT, magnetic resonance imaging-MRI and echocardiography) can record events between 5 to 100 times per second, thus substantially slower than ECG. In the case of 3D echo, CT and MRI, the problem is further confounded by the necessity to create images over multiple heartbeats where only portions of the image are obtained in a single heartbeat.A breakthrough in imaging of the heart at very high acquisition rates (physiologic rate imaging) is needed to further advance our understanding of the relationship of electrical, mechanical and flow events. Because of current slow imaging rates, it is likely that certain cardiac abnormalities remain undetectable. Developing a method to link these various cardiac activities holds a promise of providing a much more detailed understanding of how the heart works in normal and abnormal conditions with a potential to detect heart diseases earlier and to evaluate the results of current therapies more precisely and understand the impact of major risk factors such as diabetes and hypertension on the myocardium to open for new therapies. Moreover, echocardiography would improve the understanding of arrhythmia development for electrophysiology procedures and shorten procedure time and minimize patient risk.

SOLUTION

 
With a high-speed echocardiographic system Heart will change the way a heartbeat is understood from a diagnostic perspective. This means:
  • Diagnostic improvement for heart failure and tailored therapy with heart failure devices
  • Improved arrhythmia detection
  • Increased capability in detection of hypertrophy, fibrosis and scar
  • Potential to identify subclinical heart disease
  • Reduced need for MRI and CT
  • Substantially reduced acquisition time.
Gavilan scientist playing chess with green virus

Gavilán Biodesign

MANAGEMENT:
DUKE INVENTOR: Bruce Donald, Jonathan Jou, Marcel Frenkel, Mark Hallen
gavilanbio.com

Gavilán Biodesign combines state of the art physics-based modeling with our unique high accuracy AI platform to computationally screen trillions of molecules in order to find therapeutics that can overcome resistance. Gavilán is the first to add the dimension of evolution and time in our screens! We do this through our proprietary design software suite called Sylph that can design both biologics and small molecules for specificity and resistance resilience.   

gavilan logo

Our algorithms are based on rigorous mathematical guarantees allowing us to make confident predictions about our chemical space and continuously improve our predictions through improvements to our entropy-aware, continuously flexible, high accuracy biophysical models that are already the most sophisticated models of their kind for combinatorial drug design.

Explore Beyond, Leave Nothing Unseen

Gavilán Biodesign uses its proprietary computational chemistry approach to develop novel antineoplastic therapeutics that are resilient to the emergence of drug resistance. The ability of cancer to develop resistance to therapeutics is the number one contributing force to mortality. Gavilan is building on the success of the OSPREY software package developed in the Donald lab at Duke University, expanding it to not only predict but also design new molecules capable of overcoming drug resistance.

The Science

Gavilán is a results-oriented company that believes that accuracy of predictions is paramount. Therefore, Gavilán utilizes state-of-the-art algorithms that are guaranteed to find the best results within our chemical space despite our screens routinely having trillions of molecules. Nothing is left unseen: our algorithms guarantee no good compound is left behind and no resistance mutation gets through. As our accuracy is only limited by our physical models, Gavilán builds the most sophisticated models of any group performing combinatorial computational chemistry by taking into account entropy and continuous flexibility.

Phitonex

MANAGEMENT: Mike Standinsky
DUKE INVENTOR: Alvin Lebeck, Chris Dwyer
phitonex.com

Phitonex, Inc. is bringing a new way of thinking about fluorescence and experimental design to the life science laboratory. We will transform the way light is used in life science with a first focus on single cells, the fundamental unit of health and disease.

Phitonex logo

We have developed a platform that allows us to deterministically engineer optical properties to provide high resolution analysis of single cells by flow cytometry, and in the future, other applications. Lower noise, less spectral overlap, and fluorescence-by-design means that our dyes immediately unlock a higher number of parameters across current instrumentation and provide unmatched cell population resolution to drive enhanced biological insight.

We are also the first team to develop, design, and validate spectral dyes.

laptop image of phitonex product showing before and after

Phitonex uses a DNA nanotechnology platform to create highly customizable, deterministic fluorescent nanoparticles called Phitons™. This platform enables rapid innovation of labels across the spectrum with high FRET efficiencies, minimized cross-excitation, and reduced spectral spillover.

Our line of NovaFluor™ labels provide cleaner fluorescence signals with reduced cross-excitation for maximizing channel utilization.

Our upcoming InfiniFluors™ offer custom spectral signatures for greater multiplexing in spectral cytometers.

CasTag Invivo image in purple and green

CasTag Biosciences

MANGEMENT: Ed Field
DUKE INVENTOR: Scott Soderling
castagbio.com

HOMOLOGY-INDEPENDENT UNIVERSAL GENOME ENGINEERING -HIUGE-

HiUGE is a CRISPR-based solution for easy labeling of your endogenous proteins in cells or tissue. Traditional antibody approaches developed in the 1970s to study proteins are plagued by non-specific binding to other proteins, lot-to-lot variability, and are difficult to experimentally validate. In contrast, labeling with HiUGE enables researchers the ability to visualize and study their proteins of interest with the high degree of specificity and reproducibility afforded by modern molecular biology.

Our products consists of two Adeno-associated viruses: a gene-specific gRNA virus that directs the cutting of your gene at the N- or C-terminus coding region of your protein; and a payload virus that delivers epitope tags, fluorescent proteins, or premature stop codons to be incorporated into your protein.

Highlights

  • Novel CRISPR gene editing technology to allow functional studies of proteins.

  • Enables consistent detection of any protein of interest in cells or tissue, regardless of species.

  • Powerful solution for researchers that have no validated reagents developed for their targets.

  • Validated in vitro in mouse and human.

  • Validated in vivo in tissue.

  • Peer-reviewed publication in Neuron.

castag logo

STUDY ENDOGENOUS PROTEINS WITH PRECISION

CasTag provides three different custom AAV kits to label or functionally manipulate your proteins of interest in cells or tissue. Label your proteins with antibody epitopes or fluorescent proteins to visualize them with unprecedented specificity and ease. Or truncate them to study their functions. The choice is yours!

OUR KITS, YOUR PROTEINS

EpiTag labels your protein with antibody epitopes for your immunostaining needs.
FluorTag adds GFP to your endogenous proteins for live imaging.
DisrupTag inserts an epitope tag and premature stop codon to disrupt your protein exactly where you specify.

Medical blue background with pills

Sisu Pharmaceuticals

MANAGEMENT: Sean O’Brian
DUKE INVENTOR: Dennis Thiele, Jiaoti Huang

Sisu Pharma is dedicated to developing targeted drugs for patients with therapy-resistant Prostate Cancer. Prostate Cancer is the second most common cancer in men worldwide and there were over 1.3 million new cases of the disease globally in 2018. There are several treatments available for Prostate Cancer but none are curative and prolonged treatment inevitably results in resistance and death. Sisu Pharma’s proprietary technology specifically targets a key protein that is critical to the survival and spread of advanced Prostate Cancer, providing desperately needed treatment for patients with no remaining options.

sisu pharma logo